| Dates | Principal
Investigator(s) | Grant No./
Donor | Title | Goal |
|---|
| 7/20-6/25 |
Ralph Mason, PhD |
1R01CA244579, NIH/NCI |
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer |
To develop the application of a novel vascular disrupting agent (VDA) in combination with leading therapies to enhance treatment of renal cell carcinoma (RCC) and improve tumor control. |
| 8/15-7/21 |
Carlos Arteaga, MD
Ralph Mason, PhD: Director of Small Animal Imaging Resource
|
P30 CA142543, NIH/NCI |
UT Southwestern Cancer Center Support Grant |
To support the infrastructure for the promotion of interdisciplinary, translational cancer research through the efforts of senior leadership, five scientific research programs, six shared resources, protocol specific research, protocol review and monitoring, planning and evaluation activities, developmental funds, community outreach and engagement, education and training, and administration. |
| 3/20-2/23 |
Li Zhang, PhD/ Li Liu, PhD
Co-investigator: Ralph Mason, PhD
|
RP200021, CPRIT |
Optimizing Therapeutic Strategies Against Lung Cancer Using Multi-Modality Imaging |
To determine the degree to which CycT (cyclopamine tartrate) and HSP2 (heme-sequestering peptide 2) alleviate tumor hypoxia and normalize tumor vasculature |
| 7/17-6/22 |
Alex Lippert, PhD (SMU)
Local PI: Ralph Mason, PhD
|
NSF 1653474; subcontract from Southern Methodist University |
Triggered Energy Transfer Chemiluminescence for In Vivo Imaging |
To develop novel chemiluminescent reporter molecules to study physiology. |
| 7/19-6/21 |
Leo L Cheng, PhD (MGH)
Local PI: Ralph Mason, PhD
|
R21 CA243255, NIH/NCI; subcontract from Massachusetts General Hospital |
Probing Prostate Cancer Bioactivity with Polyamine Dynamics |
To develop hyperpolarized polyamine substrates as metabolic indicators of prostate cancer. |
